PRESS RELEASES
Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn
Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn. Revenues for the three months ended March 31, 2025, totaled $586 thousand. The Company’s CDMO unit began generating revenues in the second quarter ended June 30, 2024. As disclosed in the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on May 7, 2025, CDMO revenues for the full year 2024 were $658 thousand. The year-over-year increase in revenues for the first quarter of 2025 reflects a higher number of contracts executed during the period, driven by continued growth in the CDMO business.
Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences
Scinai CEO, Mr. Amir Reichman, and Chairman of the Board, Mr. Mark Germain, will attend the IATI Mini Mixiii Conference in Miami, FL on Jan 9, 2025 and the JP Morgan HealthCare Conference week in San Francisco from Jan 13-15, 2025. On Jan 14, 2025, Mr. Reichman and Mr. Germain will also participate in the SIC Biotech Symposium in San Francisco.
Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.
Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.
Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board
Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board
Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million
Scinai Publishes Financial Results and Provides Business Update; Shareholders’ Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million
Scinai Leadership to Showcase Company’s cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices unit, today announced that it will be showcasing its innovative I&I product pipeline in partnership meetings and exhibiting its CDMO services at the BIO-Europe 2024 conference, taking place November 4-6 in Stockholm, Sweden.
Scinai’s CEO, Mr. Amir Reichman, and CTO, Dr. Dalit Weinstein-Fischer will be holding meetings during the conference days with:
· Prospective clients of the company’s end-to-end biologics CDMO services.
· Potential pharma partners in the field of I&I interested in co-developing or in-licensing one of Scinai’s innovative NanoAbs.
· Potential pharma partners in the field of dermatology interested in Scinai’s drug development program for local treatment of mild to moderate plaque psoriasis – “the Botox-like solution for psoriatic patients”
· Institutional and private investors interested in SCNI’s value proposition.
Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies
Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies
Scinai Announces Signing of Loan Restructuring Agreement withEuropean Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity
Scinai Announces Signing of Loan Restructuring Agreement with the European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity
Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb
Positive Regulatory Feedback on the path for Phase 1/2a in Plaque Psoriasis